1356491-83-2

Upstream product

• 1356491-88-7 methyl 5-({(2S,5R)-1-(tert-butoxycarbonyl)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)pyridine-2-carboxylate 
• 1356491-87-6 methyl 5-({(2S,5R)-1-(tert-butoxycarbonyl)-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pyrrolidin-2-yl}methyl)pyridine-2-carboxylate 
• 1356491-86-5 methyl 5-({(2S,5R)-5-[(R)-[tert-butyl(dimethyl)silyl]oxy(phenyl)methyl]pyrrolidin-2-yl}methyl)pyridine-2-carboxylate 
• 1356491-85-4 methyl 5-{(5R,6R)-5-amino-6-{[tert-butyl(dimethyl)silyl]oxy}-6-phenylhex-1-yn-1-yl}pyridine-2-carboxylate 
• 1356491-84-3 C₃₄H₄₂N₂O₆Si 
• 1190391-64-0 4-methoxybenzyl {(1R)-1-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pent-4-yn-1-yl}carbamate 
• 1190391-63-9 (R)-2-((S)-phenyl((trimethylsilyl)oxy)methyl)hex-5-ynoic acid 
• 1190391-62-8 (2R)-2-[(S)-hydroxy(phenyl)methyl]hex-5-ynoic acid 
• 1190391-61-7 (4S)-3-{(2R)-2-[(S)-hydroxy(phenyl)methyl]hex-5-ynoyl}-4-phenyl-1,3-oxazolidin-2-one 
• 1190391-59-3 (S)-3-(hex-5-ynoyl)-4-phenyloxazolidin-2-one 
• 53293-00-8 hex-5-ynoic acid 

Downstream Products

• 1356491-98-9 tert-butyl (2R,5S)-2-[(R)-hydroxy(pheyl)methyl]-5-[(6-{[4-(pyridin-2-ylmethyl)piperazin-1-yl]carbonyl}pyridin-3-yl)methyl]pyrrolidine-1-carboxylate 
• 1356491-65-0 (R)-phenyl [(2R,5S)-5-[(6-{[(1R,5S,6s)-6-(1H-tetrazol-1-yI)-3-azabicyclo[3.1.0]hex-3yl]carbonyl}pyridin-3-yl)methyl]pyrrolidine-2-yl]methanol 
• 1356491-97-8 tert-butyl (2S,5R)-2-[(R)-hydroxy(phenyl)methyl]-5-[(6-{[(1R,5S,6S)-6-(1H-tetrazol-1-yl)-3-azabicyclo[3.1.0]hex-3-yl]carbonyl}pyridin-3-yl)methyl]pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).